Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/9/2008 First Published: 10/26/2007


1.		Phase I/II Study of Pertuzumab in Combination With Cetuximab and Irinotecan Hydrochloride in Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Temporarily closed				18 and over				NCI				DFCI-07070 07-070, 7881, NCT00551421

Last Modified: 7/2/2004 First Published: 7/26/2003


2.		Phase II Study of Pertuzumab in Patients With Hormone-Refractory Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-03048 GENENTECH-TOC2682g, NCT00066755

Last Modified: 2/12/2004 First Published: 9/24/2003


3.		Phase II Study of Pertuzumab in Patients With Advanced Refractory or Recurrent Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0303080 GENENTECH-TOC2689g, NCT00070408

Last Modified: 12/2/2004 First Published: 10/25/2004


4.		Phase II Study of Pertuzumab in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0405066-01 GENENTECH-TOC2572g, NCT00063154


5.		A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				Pharmaceutical / Industry				TOC2664g NCT00096941


6.		A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				TOC3258g NCT00096993

Last Modified: 10/10/2008 First Published: 3/3/2006


7.		Phase II Study of Trastuzumab (Herceptin®) and Pertuzumab in Patients With HER2/neu-Overexpressing Inoperable Locally Advanced or Metastatic Breast Cancer Refractory to Trastuzumab-Based Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCI-06-C-0035 NCI-P6660, NCT00301899

Select All on One Page